STOCK TITAN

Star Equity Holdings Completes Sale of DMS Health for $18.75 Million

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Star Equity Holdings (Nasdaq: STRR; STRRP) has completed the sale of DMS Health Technologies for $18.75 million in cash, enhancing its balance sheet. The divestiture, along with a previous asset sale for $1.4 million, allows the company to focus on lower capex and higher margin segments within its Healthcare division. CEO Matt Molchan stated the sales team aims to expand its client base for Digirad branded imaging products. This strategic move positions Star Equity for future acquisitions and investments in high-return sectors.

Positive
  • Sale of DMS Health for $18.75 million improves balance sheet.
  • Focus on lower capex, higher margin segments in Healthcare.
  • Potential for future acquisitions and investments in high-return sectors.
Negative
  • None.

OLD GREENWICH, Conn., April 01, 2021 (GLOBE NEWSWIRE) -- Star Equity Holdings (Nasdaq: STRR; STRRP) (“Star Equity” or the “Company”), a diversified holding company with three divisions: Healthcare, Construction, and Investments, announced today the completion of the sale of DMS Health Technologies, Inc. (“DMS Health”), the Company’s Mobile Healthcare business, for $18.75 million in cash, as originally announced on November 3, 2020.

Matt Molchan, CEO of Digirad Health, Inc., the Company’s Healthcare division, said, “Following the divestiture of DMS Health and another small asset sale completed on February 1, 2021 for $1.4 million, we have now streamlined our portfolio of healthcare assets and services by focusing our efforts on lower capex, higher margin segments within our Healthcare division. Our sales team is now focused on new opportunities to expand our client base and geographic footprint for selling and servicing our Digirad branded solid-state imaging cameras and on-site camera rental services.”

Jeff Eberwein, Star Equity’s Executive Chairman, noted, “The sale of assets in Q1 2021 has substantially improved our balance sheet and enables us to fund high-return internal growth investments as well as pursue acquisitions which could be bolt-ons in Healthcare or Construction or entry into a new business sector.”

About Star Equity Holdings, Inc.
Star Equity Holdings, Inc. is a diversified holding entity with three divisions: Healthcare, Construction, and Investments.

Healthcare
Digirad Health designs, manufactures, and distributes diagnostic medical imaging products and provides mobile imaging services. Digirad Health operates in two businesses: (i) diagnostic services and (ii) diagnostic imaging. The diagnostic services business offers imaging services to healthcare providers as an outsourced alternative to purchasing and operating their own equipment. The diagnostic imaging business develops, sells, and maintains solid-state gamma cameras.

Construction
Star Modular Construction manufactures modular housing units for commercial and residential real estate projects and operates in two businesses: (i) modular building manufacturing and (ii) structural wall panel and wood foundation manufacturing, including building supply retail operations.

Investments
Star Investments manages and finances the Company’s real estate assets and investments.

Forward-Looking Statements
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this release that are not statements of historical fact are hereby identified as “forward-looking statements” for the purpose of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking Statements include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to acquisitions and related integration, development of commercially viable products, novel technologies, and modern applicable services, (ii) projections of income (including income/loss), EBITDA, earnings (including earnings/loss) per share, free cash flow (FCF), capital expenditures, cost reductions, capital structure or other financial items, (iii) the future financial performance of the Company or acquisition targets and (iv) the assumptions underlying or relating to any statement described above. Moreover, forward-looking statements necessarily involve assumptions on the Company’s part. These forward-looking statements generally are identified by the words “believe”, “expect”, “anticipate”, “estimate”, “project”, “intend”, “plan”, “should”, “may”, “will”, “would”, “will be”, “will continue” or similar expressions. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described above as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the substantial amount of debt of the Company and the Company’s ability to repay or refinance it or incur additional debt in the future; the Company’s need for a significant amount of cash to service and repay the debt and to pay dividends on the Company’s preferred stock; the restrictions contained in the debt agreements that limit the discretion of management in operating the business; legal, regulatory, political and economic risks in markets and public health crises that reduce economic activity and cause restrictions on operations (including the recent coronavirus COVID-19 outbreak); the length of time associated with servicing customers; losses of significant contracts or failure to get potential contracts being discussed; disruptions in the relationship with third party vendors; accounts receivable turnover; insufficient cash flows and resulting lack of liquidity; the Company's inability to expand the Company's business; unfavorable changes in the extensive governmental legislation and regulations governing healthcare providers and the provision of healthcare services and the competitive impact of such changes (including unfavorable changes to reimbursement policies); high costs of regulatory compliance; the liability and compliance costs regarding environmental regulations; the underlying condition of the technology support industry; the lack of product diversification; development and introduction of new technologies and intense competition in the healthcare industry; existing or increased competition; risks to the price and volatility of the Company’s common stock and preferred stock; stock volatility and in liquidity; risks to preferred stockholders of not receiving dividends and risks to the Company’s ability to pursue growth opportunities if the Company continues to pay dividends according to the terms of the Company’s preferred stock; the Company’s ability to execute on its business strategy (including any cost reduction plans); the Company’s failure to realize expected benefits of restructuring and cost-cutting actions; the Company’s ability to preserve and monetize its net operating losses; risks associated with the Company’s possible pursuit of acquisitions; the Company’s ability to consummate successful acquisitions and execute related integration, as well as factors related to the Company’s business including economic and financial market conditions generally and economic conditions in the Company’s markets; failure to keep pace with evolving technologies and difficulties integrating technologies; system failures; losses of key management personnel and the inability to attract and retain highly qualified management and personnel in the future; and the continued demand for and market acceptance of the Company’s services. For a detailed discussion of cautionary statements and risks that may affect the Company’s future results of operations and financial results, please refer to the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the risk factors in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. This release reflects management’s views as of the date presented.

All forward-looking statements are necessarily only estimates of future results, and there can be no assurance that actual results will not differ materially from expectations, and, therefore, you are cautioned not to place undue reliance on such statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.

For more information contact: 
Star Equity Holdings, Inc.The Equity Group
Jeffrey E. EberweinLena Cati
Executive ChairmanVice President
203-489-9501212-836-9611
admin@starequity.comlcati@equityny.com


FAQ

What is the recent sale amount for DMS Health Technologies by Star Equity Holdings?

Star Equity Holdings sold DMS Health Technologies for $18.75 million in cash.

What are the main focuses of Star Equity's Healthcare division after the asset sale?

The Healthcare division is now focusing on lower capex and higher margin segments.

What was the amount of the previous asset sale completed by Star Equity in February 2021?

The previous asset sale completed in February 2021 was for $1.4 million.

What potential opportunities is Star Equity pursuing following the divestiture?

Star Equity is looking to pursue acquisitions and high-return internal growth investments.

Star Equity Holdings, Inc.

NASDAQ:STRR

STRR Rankings

STRR Latest News

STRR Stock Data

6.69M
2.28M
28.92%
8.62%
1.01%
Diagnostics & Research
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
OLD GREENWICH